Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Latest Trials

Trial Type
Systemic therapy trial

SURF301 : A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and...

This phase I/II study is evaluating how safe, tolerable and effective a new drug (TYRA-300) is in people certain cancers with FGFR3 activating gene alterations

Status : Recruiting

Trial Type
Systemic therapy trial

EMBER-4 : EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard...

This phase III study is measuring how well a new hormone therapy (imlunestrant) works compared to standard hormone therapy (tamoxifen, anastrozole, letrozole, or exemestane) in people with early breast cancer that is ER+ and HER2-

Status : Recruiting

Trial Type
Systemic therapy trial

RELATIVITY : A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With...

This phase II trial aims to assess the safety of two types of immunotherapy (nivolumab and relatlimab) in combination with chemotherapy, to determine if it will improve survival outcomes for people with untreated Stage IV or recurrent non-small cell lung cancer, compared to using one type of immunotherapy (nivolumab) and chemotherapy for the treatment of people with this type of cancer

Status : Recruiting

Trial Type
Systemic therapy trial

CONTACT-02 : A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in...

This phase III trial is comparing a type of targeted therapy with a novel hormonal therapy (NHT) in men who have previously received one NHT for their castration resistant prostate cancer that has spread to other parts of the body

Status : Recruiting

Trial Type
Systemic therapy trial

EVOKE-01 : Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan...

This phase III trial is trying to determine whether targeted therapy (Sacituzumab Govitecan-hziy) is more effective than chemotherapy (Docetaxel) in people with advanced or metastatic non-small cell lung cancer who have had previous treatment

Status : Recruiting

Trial Type
Systemic therapy trial

ACE-Breast03 : A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients...

This Phase II trial is trying to understand the effectiveness of a new targeted therapy (ARX788) in people with HER2-positive metastatic breast cancer who have not responded to other targeted therapies (T-DM1, T-DXd, Tucatinib)

Status : Recruiting

Trial Type
Systemic therapy trial

HER2CLIMB-05 : A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With...

This phase III study is trying to understand whether targeted therapy (tucatinib) works better than placebo when given with other drugs (trastuzumab and pertuzumab) to treat people with HER2-positive breast cancer.

Status : Recruiting

Trial Type
Surgical trial

Decrescendo : De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative,...

This phase II study is evaluating the effectiveness of chemotherapy (paclitaxel or docetaxel) combined with targeted therapy (pertuzumab and trastuzumab), followed by surgery, followed by further treatment with targeted therapy or chemotherapy, in people with HER2-positive, ER-negative, Node-negative early breast cancer

Status : Recruiting

Trial Type
Systemic therapy trial

PACIFIC-9 : A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International...

This phase III trial is testing different combinations of targeted therapy in people with locally advanced non-small cell lung cancer that has not progressed on prior chemoradiotherapy treatment and is unable to be surgically removed

Status : Recruiting

Trial Type
Systemic therapy trial

LAGOON : A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or...

This phase III study is comparing how safe and effective an alkylating drug (lurbinectedin) is alone, or when combined with chemotherapy (irinotecan), compared to chemotherapy alone (irinotecan or topotecan) in people with relapsed small-cell lung cancer

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.